124 related articles for article (PubMed ID: 38770733)
21. Effect of financial incentives on breast, cervical and colorectal cancer screening delivery rates: Results from a systematic literature review.
Mauro M; Rotundo G; Giancotti M
Health Policy; 2019 Dec; 123(12):1210-1220. PubMed ID: 31587819
[TBL] [Abstract][Full Text] [Related]
22. Breast, Cervical, and Colorectal Cancer Screening Adherence: Effect of Low Body Mass Index in Women.
Charkhchi P; Schabath MB; Carlos RC
J Womens Health (Larchmt); 2020 Jul; 29(7):996-1006. PubMed ID: 31928405
[No Abstract] [Full Text] [Related]
23. Resilience of the Dutch HPV-based cervical screening programme during the COVID-19 pandemic.
Olthof EMG; Aitken CA; Siebers AG; van Kemenade FJ; de Kok IMCM
Public Health; 2024 Feb; 227():42-48. PubMed ID: 38103276
[TBL] [Abstract][Full Text] [Related]
24. Cancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation.
Basu P; Alhomoud S; Taghavi K; Carvalho AL; Lucas E; Baussano I
JCO Glob Oncol; 2021 Mar; 7():416-424. PubMed ID: 33784177
[TBL] [Abstract][Full Text] [Related]
25. "It's cancer screening after all". Barriers to cervical and colorectal cancer screening and attitudes to promotion of self-sampling kits upon attendance for breast cancer screening.
Kirkegaard P; Larsen MB; Andersen B
J Med Screen; 2023 Jun; 30(2):74-80. PubMed ID: 36541340
[TBL] [Abstract][Full Text] [Related]
26. Effects of cancer screening restart strategies after COVID-19 disruption.
Kregting LM; Kaljouw S; de Jonge L; Jansen EEL; Peterse EFP; Heijnsdijk EAM; van Ravesteyn NT; Lansdorp-Vogelaar I; de Kok IMCM
Br J Cancer; 2021 Apr; 124(9):1516-1523. PubMed ID: 33723386
[TBL] [Abstract][Full Text] [Related]
27. [Cancer screening programme in health care workers].
Pisati G; Cerri S; Marinelli M; Tedeschi B; Valsecchi E
G Ital Med Lav Ergon; 2011; 33(2 Suppl):57-60. PubMed ID: 22187927
[TBL] [Abstract][Full Text] [Related]
28. [Cancer screening programmes in Italy: unification element or factor for further division?].
Zappa M; Federici A; Salmaso S
Epidemiol Prev; 2011; 35(5-6 Suppl 2):100-2. PubMed ID: 22166878
[No Abstract] [Full Text] [Related]
29. A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
Joung RH; Nelson H; Mullett TW; Kurtzman SH; Shafir S; Harris JB; Yao KA; Brajcich BC; Bilimoria KY; Cance WG
Cancer; 2022 Jun; 128(11):2119-2125. PubMed ID: 35307815
[TBL] [Abstract][Full Text] [Related]
30. History, development and future of cancer screening in Australia.
Olver IN; Roder D
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765858
[TBL] [Abstract][Full Text] [Related]
31. Screening for cancer in low- and middle-income countries.
Sankaranarayanan R
Ann Glob Health; 2014; 80(5):412-7. PubMed ID: 25512156
[TBL] [Abstract][Full Text] [Related]
32. Reasons for non-participation in public oncological screening programs in the Italian region Friuli Venezia Giulia.
Valent F; Sammartano F; Degano S; Dellach C; Franzo A; Gerin D; Gnesutta D; Mentil S; Stel S; Pattitoni C; Gongolo F
Public Health; 2020 Apr; 181():80-85. PubMed ID: 31958673
[TBL] [Abstract][Full Text] [Related]
33. [Screening for colorectal cancer in Italy, 2010 survey].
Zorzi M; Fedato C; Grazzini G; Sassoli de' Bianchi P; Naldoni C; Pendenza M; Sassatelli R; Senore C; Visioli CB; Zappa M
Epidemiol Prev; 2012; 36(6 Suppl 1):55-77. PubMed ID: 23293271
[TBL] [Abstract][Full Text] [Related]
34. Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.
Rutter CM; Kim JJ; Meester RGS; Sprague BL; Burger EA; Zauber AG; Ergun MA; Campos NG; Doubeni CA; Trentham-Dietz A; Sy S; Alagoz O; Stout N; Lansdorp-Vogelaar I; Corley DA; Tosteson ANA
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):158-164. PubMed ID: 29150480
[No Abstract] [Full Text] [Related]
35. Participation in interventions and recommended follow-up for non-attendees in cervical cancer screening -taking the women's own preferred test method into account-A Swedish randomised controlled trial.
Lilliecreutz C; Karlsson H; Spetz Holm AC
PLoS One; 2020; 15(7):e0235202. PubMed ID: 32614875
[TBL] [Abstract][Full Text] [Related]
36. Socioeconomic factors affecting colorectal, breast and cervical cancer screening in an Asian urban low-income setting at baseline and post-intervention.
Wee LE; Koh GC; Chin RT; Yeo WX; Seow B; Chua D
Prev Med; 2012 Jul; 55(1):61-7. PubMed ID: 22561028
[TBL] [Abstract][Full Text] [Related]
37. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
38. Cancer worries and uptake of breast, cervical, and colorectal cancer screening: A population-based survey in England.
Quaife SL; Waller J; von Wagner C; Vrinten C
J Med Screen; 2019 Mar; 26(1):3-10. PubMed ID: 30249158
[TBL] [Abstract][Full Text] [Related]
39. Intentions to participate in cervical and colorectal cancer screening during the COVID-19 pandemic: A mixed-methods study.
Wilson R; Quinn-Scoggins H; Moriarty Y; Hughes J; Goddard M; Cannings-John R; Whitelock V; Whitaker KL; Grozeva D; Townson J; Osborne K; Smits S; Robling M; Hepburn J; Moore G; Gjini A; Brain K; Waller J
Prev Med; 2021 Dec; 153():106826. PubMed ID: 34599921
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
